ImmunoTherapyNews.net

Cancer immunotherapy

XagenaNewsletter
Xagena Mappa
Medical Meeting
Reumabase.it

Search results for "Metastatic melanoma"

The anti-programmed death-1 ( PD-1 ) antibody Nivolumab ( Opdivo ) has clinical activity in patients with metastatic melanoma. Nivolumab plus vaccine was investigated as adjuvant therapy in resected ...


Nivolumab ( Opdivo ) was associated with higher rates of objective response than chemotherapy in a phase 3 study involving patients with Ipilimumab-refractory metastatic melanoma. The use of Nivolum ...


Adoptive cell therapy ( ACT ) for cancers using autologous tumor-infiltrating lymphocytes ( TILs ) can induce immune responses and antitumor activity in metastatic melanoma patients. Researchers a ...


Both Ipilimumab, an anti–cytotoxic T-lymphocyte–associated antigen 4 monoclonal antibody ( Yervoy ) and Nivolumab, an anti–programmed death 1 monoclonal antibody ( Opdivo ), have been approved by the ...


The results of the pivotal OPTiM study have shown that Talimogene laherparepvec monotherapy is the first oncolytic immunotherapy to demonstrate therapeutic benefit in a phase 3 trial for patients with ...


Uveal melanomas are a rare type of melanoma with only 5-7 cases per 1 million persons diagnosed each year. Patients with metastatic melanoma of uveal origin, tend to have lower response rates on tradi ...


Brain metastases develop in 40% of metastatic melanoma patients. Untreated brain metastases exclude from most clinical trials. In prior trials, treatment of metastatic melanoma with Pembrolizumab ( Ke ...


The indoleamine 2,3-dioxygenase ( IDO ) pathway is a key counter-regulatory mechanism that normally inhibits immune responses when appropriate. In the setting of cancer, IDO pathway-mediated immune ...